MK-3475-03A
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
- NCT04626479 ↗
- Completed
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on MK-3475-03A (pembrolizumab/quavonlimab plus lenvatinib; favezelimab/pembrolizumab plus lenvatinib; belzutifan plus pembrolizumab plus lenvatinib in first-line advanced clear-cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MK-3475-03A so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03A in First Line Metastatic Participants
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pembrolizumab; Favezelimab/Pembrolizumab; Belzutifan; Lenvatinib; Pembrolizumab/Quavonlimab; Vibostolimab/Pembrolizumab
- Arms
- Coformulation Pembrolizumab/Quavonlimab + Lenvatinib · Experimental
- Coformulation Favezelimab/Pembrolizumab+ Lenvatinib · Experimental
- Pembrolizumab + Belzutifan + Lenvatinib · Experimental
- Pembrolizumab + Lenvatinib · Experimental
- Coformulation Vibostolimab/Pembrolizumab+Belzutifan · Experimental
- Enrollment
- 393
- Primary outcomes
- Safety Lead-in Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)
- Safety Lead-in Phase: Number of participants who experience one or more adverse events (AEs)
- Safety Lead-in Phase: Number of participants who discontinue study treatment due to an AE
- Efficacy Phase: Number of participants who experience one or more DLTs
- Efficacy Phase: Number of participants who experience one or more AEs
- Efficacy Phase: Number of participants who discontinue study treatment due to an AE
- Efficacy Phase: Objective response rate (ORR)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Dec 16, 2020
- Primary completion
- Aug 10, 2026
- Results posted
- No
- Registry record
- NCT04626479 · updated Sep 25, 2026
Publications
linked from the registry- Suarez C, Rojas C, Shin SJ, Yanez Weber P, Albiges L, Motzer R, Hammers H, Peer A, Lee JL, Miller WH, Waddell T, Neiman V, Keizman D, Zwenger Kloster A, Weickhardt A, Dziadziuszko R, Suttner L, Sharma M, Burgents JE, Powles T. Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial. Ann Oncol. 2026 Feb;37(2):229-240. doi: 10.1016/j.annonc.2025.10.010. Epub 2025 Oct 18. PubMed 41115468